Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II open-label study designed to evaluate the combination of pembrolizumab
and cabozantinib in subjects with locally advanced, recurrent, or metastatic renal cell
carcinoma. Sequential dose escalation of cabozantinib with standard dose pembrolizumab will
occur in the phase I dose escalation part of the study to determine the recommended phase 2
dose (RP2D). Subsequently, subjects will receive cabozantinib at the RP2D in combination with
pembrolizumab in the phase II dose expansion part of the study.